65185-41-3

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-quinoline-2-carbonitrile is used as a synthetic intermediate for the development of new pharmaceutical compounds. Its unique structure allows for the creation of a wide range of derivatives with potential therapeutic applications.
Used in Chemical Research:
In the field of chemical research, 6-bromo-quinoline-2-carbonitrile serves as a valuable starting material for the synthesis of various complex organic molecules. Its reactivity and structural features make it a useful tool for exploring new chemical reactions and pathways.
Used in Material Science:
6-Bromo-quinoline-2-carbonitrile is used as a component in the development of new materials with specific properties. Its incorporation into polymers or other materials can lead to the creation of novel materials with improved characteristics, such as enhanced stability or increased reactivity.
It is important to handle 6-bromo-quinoline-2-carbonitrile with care, as it may pose certain risks and hazards in handling and storage. The properties of this chemical substance, such as molecular weight, density, boiling point, melting point, and flash point, can be determined through various laboratory methods.

InChI:InChI=1/C10H5BrN2/c11-8-2-4-10-7(5-8)1-3-9(6-12)13-10/h1-5H

Upstream product

• 5332-25-2 6-bromoquinoline 
• 773837-37-9 sodium cyanide 
• 6563-11-7 6-bromoquinoline-N-oxide 
• 877-42-9 6-Bromo-2-methyl-quinoline 
• 7677-24-9 trimethylsilyl cyanide 

Downstream Products

• 65148-09-6 6-bromoquinoline-2-carboxamide 
• 1381787-07-0 C₂₆H₂₄FNO₃S 
• 1381787-06-9 C₁₉H₁₈FNO 
• 1381787-05-8 C₁₉H₁₆FNO 
• 1381786-56-6 6-(4-Fluorophenyl)-2-(2-methyl-1-(1H-1,2,3-triazol-1-yl)propyl)quinoline 
• 1312609-35-0 C₃₉H₄₃N₇O₆ 
• 1312611-86-1 C₃₂H₃₂N₆O₃ 
• 1312611-36-1 C₃₇H₄₀N₆O₅ 
• 1312611-34-9 C₃₇H₄₀N₆O₆ 
• 1312609-37-2 C₄₀H₃₈N₆O₄ 
• 1312609-41-8 C₃₈H₄₂N₈O₆ 
• 1312611-26-9 C₃₈H₄₂N₈O₇ 
• 1312609-34-9 C₃₈H₄₂N₈O₆ 
• 1312611-25-8 C₃₁H₃₁N₇O₃ 

Relevant academic research and scientific papers

Quinoline-Flanked Diketopyrrolopyrrole Copolymers Breaking through Electron Mobility over 6 cm2 V?1 s?1 in Flexible Thin Film Devices

Herein, the design and synthesis of novel π-extended quinoline-flanked diketopyrrolopyrrole (DPP) [abbreviated as QDPP] motifs and corresponding copolymers named PQDPP-T and PQDPP-2FT for high performing n-type organic field-effect transistors (OFETs) in flexible organic thin film devices are reported. Serving as DPP-flankers in backbones, quinoline is found to effectively tune copolymer optoelectric properties. Compared with TDPP and pyridine-flanked DPP (PyDPP) analogs, widened bandgaps and strengthened electron deficiency are achieved. Moreover, both hole and electron mobility are improved two orders of magnitude compared to those of PyDPP analogs (PPyDPP-T and PPyDPP-2FT). Notably, featuring an all-acceptor-incorporated backbone, PQDPP-2FT exhibits electron mobility of 6.04 cm2 V?1 s?1, among the highest value in OFETs fabricated on flexible substrates to date. Moreover, due to the widened bandgap and strengthened electron deficiency of PQDPP, n-channel on/off ratio over 105 with suppressed hole transport is first realized in the ambipolar DPP-based copolymers.

COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS

The instant invention describes pharmaceutical compositions and dosing regimens comprising radiation therapy and seviteronel with or without dexamethasone, and methods of treating diseases, disorders or symptoms thereof.

Hypervalent Iodine(III)-Mediated Regioselective Cyanation of Quinoline N-Oxides with Trimethylsilyl Cyanide

A regioselective cyanation of quinoline N-oxides with trimethylsilyl cyanide was developed by using (Diacetoxyiodo) benzene (PIDA) as mediated hypervalent iodine(III) reagent under metal-free and base-free reaction conditions to obtain 2-cyanoquinolines. The efficient PIDA reagent could play the role of an activator of the substrates and an accelerator of N?O bond cleavage. The reaction system featured a wide range of substrate suitability and high yields. The procedure was enlarged gram-scale to synthesize the tuberculosis (TB) inhibitor. Finally, according to some experimental results, a plausible mechanism for the cyanation reaction is proposed. (Figure presented.).

COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS

The instant invention describes pharmaceutical compositions and dosing regimens comprising seviteronel and/or dexamethasone, and methods of treating diseases, disorders symptoms thereof.

Synthesis method of 2-cyanoquinoline derivative

The invention discloses a synthesis method of a 2-cyanoquinoline derivative, and belongs to the technical field of synthesis methods of chinoline and derivatives thereof. The synthesis method includes: adopting a compound represented as in formula (I) and trimethylsilyl cyanide as raw materials, dissolving the raw materials in an organic solvent, catalyzing with H-diethyl phosphite and carbon tetrachloride, and adopting alkali as a deacid reagent to prepare a compound represented as in formula (II). The synthesis method of the 2-cyanoquinoline derivative has the advantages that the adopted catalysts are low in cost and easy to obtain, the raw materials are easy to store, reaction conditions are mild, experimental operations are simple, the obtained 2-cyanoquinoline derivative products are easy to purify, high yield and applicability to industrial production are realized, and a novel synthesis method for preparing the 2-cyanoquinoline derivative is provided.

Iodine-catalyzed ammoxidation of methyl arenes

The development of organic transformation using cheap and readily available substrates under mild conditions will be pivotal for green and sustainable synthetic organic chemistry. Concerning our continued interest in the cyanation reaction, a metal-free direct ammoxidation of readily available methyl arenes leading to nitriles was established under mild conditions. A series of aryl methanes especially heteroaryl methanes (30 examples) were applicable in moderate to good yields with good functionality tolerance.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.